AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback

AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback·Investor's Business Daily

AbbVie stock popped Friday after an analyst upgraded it on the remaining opportunity for its Cerevel takeover despite a huge misstep.

Advertisement